When a treatment gains clinical momentum faster than the evidence supporting it, patient outcomes can diverge dramatically from intent. Focal therapy — the targeted ablation of prostate tumors rather than whole-gland treatment — has attracted growing interest as a middle path between active surveillance and radical intervention, yet its real-world adoption patterns across U.S. cancer centers warrant careful scrutiny.
This retrospective analysis drew on National Cancer Database records to characterize how focal therapy is being deployed across risk strata. The investigators found measurable use of focal approaches in both low-risk patients, who are generally candidates for surveillance rather than any ablation, and in high- or very-high-risk patients, where systemic and whole-gland treatments carry stronger evidence. Intermediate-risk disease — the population with the most plausible theoretical benefit from focal techniques — was also examined, revealing heterogeneity in how centers define and apply eligibility criteria.
The broader context here is important. Focal therapies — including high-intensity focused ultrasound (HIFU), cryoablation, and irreversible electroporation — have accumulated mostly single-arm, short-term evidence. No large randomized controlled trial has yet demonstrated equivalent oncologic outcomes to radical prostatectomy or radiation in intermediate-risk disease. Major guidelines from NCCN and EAU classify focal therapy as investigational or appropriate only within clinical trial settings for most risk groups. This database study therefore functions as a practice audit rather than an efficacy assessment, and its signal is concerning: real-world penetration appears to be outpacing evidence, particularly in risk categories where the harm-benefit calculus is least favorable. The study's retrospective design and reliance on administrative coding carry inherent limitations around staging accuracy and treatment intent. Nonetheless, findings like these provide a necessary counterweight to enthusiasm, reminding clinicians and patients that novelty is not equivalence.